MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

NCT04784897 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-09-16

Study results available
· View outcomes & findings →

Summary

The study assessed the efficacy and safety of Brilacidin for the treatment of COVID-19 in hospitalized participants

Conditions

Interventions

DRUG

Brilacidin

Brilacidin IV infusion

DRUG

Placebo

Placebo IV infusion

DRUG

Standard of Care (SoC)

SoC therapies for COVID-19

Sponsors & Collaborators

  • Innovation Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Innovation Pharmaceuticals Inc. · Innovation Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-22
Primary Completion
2021-07-01
Completion
2021-07-30
FDA Drug
Yes

Countries

  • United States
  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04784897 on ClinicalTrials.gov